Trial Profile

Phase 3 trial for BNT311/GEN1046 (acasunlimab) in second line NSCLC

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 08 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

05 Aug 2024 According to a BioNTech media release, the emerging clinical profile of BNT311/GEN1046 (acasunlimab) is encouraging, for reasons relating to portfolio strategy, BioNTech opted not to participate in the further development of the program, including a planned Phase 3 trial. BioNTech and Genmab A/S will continue their collaboration under the existing agreements which was expanded in 2022.
05 Aug 2024 According to a Genmab media release, company plans to initiate the Phase 3 study in the second half of this year.
20 Mar 2024 According to OmniAB media release,the company plans to initiate a Phase 3 study of acasunlimab in a second-line NSCLC indication in before year-end 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com